Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma
| Image |  |
|---|---|
| Description | scholarly article |
| Author/s |
author: Armando Santoro |
| Publication date | January 25, 2024 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |